The 3 most recent market catalysts affecting $KYTX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Bullish
Impact 75
Kyverna Therapeutics Therapy Delivers Sustained Relief in Rare Neurological Conditions
Kyverna Therapeutics reported significant positive 12-month data for its miv-cel cell therapy in two rare neurological conditions, stiff-person syndrome and generalized myasthenia …
Sep 24, 2026
Corporate Catalyst
Bullish
Impact 85
Kyverna Therapeutics shares are trading higher after the company announced ne-year topline data from KYSA-8 and topline longer-term follow-up data from the Phase 2 portion of KYSA-6.
This headline represents a major corporate catalyst for Kyverna Therapeutics. Positive topline data from clinical trials, especially from Phase 2 studies, significantly de-risks a …
Sep 24, 2026
Corporate Catalyst
Bullish
Impact 75
Kyverna Therapeutics Announces One-year Topline Data From KYSA-8, Its Trial Of Miv-Cel In Patients With Stiff Person Syndrome, And Topline Longer-Term Follow-up Data From Phase 2 Of KYSA-6, Its Trial In Patients With Generalized Myasthenia Gravis; Topline Durability Data Reinforce Potential For Single-dose Miv-Cel To Free Patients From Lifelong Disease Burden And Chronic Immunotherapies, Further Highlighting Miv-Cel’s Differentiated Construct
Kyverna Therapeutics (KYTX) released positive one-year data for its Miv-Cel trial in Stiff Person Syndrome (SPS) and longer-term follow-up data for Generalized Myasthenia Gravis (g…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.